Danisco A/S (formerly Genencor International Inc)
In March 2004, Innogenetics acquired the therapeutic vaccine programs of Danisco, taking over responsibility for all further development and commercializaton of products arising from these programs. Through this deal, Innogenetics gained access to a broad technology platform, intellectual property rights, and licenses with respect to therapeutic and prophylactic vaccine applications for HBV, HPV, and HCV.
Through this agreement, Innogenetics also acquired exclusive access to a broad portfolio of patented cytotoxic T lymphocyte (CTL) epitopes, complementary rights (including PADRE®‚ technology) as well as associated technologies.
Under this agreement, Innogenetics paid Danisco upfront license fees totaling €8.2 million within the first year. Upon achievement of various clinical development milestones, Danisco is entitled to receive additional payments.